Person:
KARAASLAN, ELİF

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Job Title
First Name
ELİF
Last Name
KARAASLAN
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 14
  • PublicationOpen Access
    Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19
    (2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
  • PublicationMetadata only
    Evaluation of CCHFV nucleoprotein as diagnostic tool in ELISA
    (2017-09-10) ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; YAZICI, MERVE; Hasanoğlu, Sevde; KALKAN, AHMET; KILIÇ, ALİ OSMAN; ÖZDARENDELİ, AYKUT; DOYMAZ, MEHMET ZİYA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; YAZICI, MERVE; DOYMAZ, MEHMET ZIYA
  • PublicationMetadata only
    Investigation Of The Cellular And Humoral Immune Responses Against Nucleoprotein Of Crimean Congo Hemorrhagic Fever Virus (CCHFV)
    (2019-05-10) ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; DOYMAZ, MEHMET ZİYA; KILIÇ, ALİ OSMAN; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; DOYMAZ, MEHMET ZIYA
  • PublicationMetadata only
    INVESTIGATION OF HUMORAL RESPONSE RAISED AGAINST BACTERIALLY EXPRESSED NUCLEOPROTEIN OF CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS
    (2016-04-27) KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; KILIÇ, ALİ OSMAN; DOYMAZ, MEHMET ZİYA; KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; DOYMAZ, MEHMET ZIYA
  • PublicationMetadata only
    Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria
    (2016-01-01T00:00:00Z) Dosler, Sibel; Karaaslan, ELİF; Gerceker, A. Alev; KARAASLAN, ELİF
    In vitro antibacterial and anti-biofilm activities of antimicrobial cationic peptides (AMPs) melittin and colistin both alone and in combination with antibiotics were evaluated against clinical isolates of Gram-negative bacteria. Minimum inhibitory concentration (MIC) and fractional inhibitory concentration (FIG) index were determined by the microbroth dilution and chequerboard techniques, respectively. The time-kill curve (TKC) method was used for determining the bactericidal activities of AMPs alone and in combination. Measurements of anti-biofilm activities were performed spectrophotometrically for both inhibition of attachment and 24-hour biofilm formation at MIC or subMIC. According to MIC, values, the most active agents against Pseudomonas aeruginosa, Escherichia colt and Klebsiella pneumoniae were colistin, imipenem and ciprofloxacin, respectively. In combination studies, synergistic effects were mostly seen with colistin imipenem against E. coif and K. pneumoniae (50 and 54%, respectively), colistin ciprofloxacin against P. aeruginosa (77%). In TKC studies, synergism was observed with almost all expected combinations, even more frequently than chequerboard method. All of the antimicrobial agents were able to inhibit attachment and 24-hour biofilm formation between 0-57% at 1/10 x MIC and 7-73% at 1 x or 1/10 x MIC, respectively. AMPs seem to be a good candidate for antimicrobial chemotherapy with their antibacterial and anti-biofilm activities as a single agent or in combination with antibiotics.
  • PublicationMetadata only
    Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides
    (2014-12-01T00:00:00Z) Dosler, Sibel; Karaaslan, Elif; KARAASLAN, ELİF
    Pseudomonas aeruginosa is one of the major nosocomial pathogen that can causes a wide variety of acute and chronic infections P. aeruginosa is a dreaded bacteria not just because of the high intrinsic and acquired antibiotic resistance rates but also the biofilm formation and production of multiple virulence factors. We investigated the in vitro activities of antibiotics (ceftazidime, tobramycin, ciprofloxacin, doripenem, piperacillin and colistin) and antimicrobial cationic peptides (AMPs; LL-37, CAMA: cecropin(1-7)melittin A(2-9) amide, melittin, defensin and magainin-II) alone or in combination against biofilms of laboratory strain ATCC 27853 and 4 clinical strains of P. aeruginosa. The minimum inhibitory concentrations (MIC), minimum bactericidal concentration (MBC) and minimum biofilm eradication concentrations (MBEC) were determined by microbroth dilution technique. The MBEC values of antibiotics and AMPs were 80->5120 and 640->640 mg/L, respectively. When combined with the LL-37 or CAMA at 1110x MBEC, the MBEC values of antibiotics that active against biofilms, were decreased up to 8-fold. All of the antibiotics, and AMPs were able to inhibit the attachment of bacteria at the 1110x MIC and biofilm formation at 1 x or 1110x MIC concentrations. Time killing curve studies showed 3-log10 killing against biofilms in 24 h with almost all studied antibiotics and AMPs. Synergism were seen in most of the studied combinations especially CAMA/LL-37 + ciprofloxacin against at least one or two strains- biofilms. Since biofilms are not affected the antibiotics at therapeutic concentrations, using a combination of antimicrobial agents including AMPs, or inhibition of biofilm formation by blocking the attachment of bacteria to surfaces might be alternative methods to fight with biofilm associated infections. (C) 2014 Elsevier Inc. All rights reserved.